Literature DB >> 8140098

Herpes thymidine kinase mutants with altered catalytic efficiencies obtained by random sequence selection.

K M Munir1, D C French, D K Dube, L A Loeb.   

Abstract

We have obtained 190 active Herpes simplex virus type 1 thymidine kinase mutants by substituting a 33 nucleotide sequence with 20% degeneracy for a portion of the nucleotide sequence that encodes the putative thymidine binding site [K.M. Munir, D.C. French, D.K. Dube and L.A. Loeb (1992) J. Biol. Chem., 167, 6584-6589]. In order to classify these mutants with respect to thymidine kinase activity we determined the ability of Escherichia coli harboring these mutants to form colonies in the presence of varying concentrations of thymidine. Escherichia coli harboring one of the mutant enzymes was able to form colonies at a concentration of thymidine lower than did the wild type. It was able to phosphorylate thymidine more rapidly than the wild type both in vivo and in vitro. The increased thymidine kinase activity was manifested by (i) a 42% enhanced uptake of [methyl-3H]thymidine into E. coli, (ii) a 2.4 times higher rate of [methyl-3H]thymidine incorporation into acid-insoluble material and (iii) a 5-fold increase in the kcat of the purified enzyme compared to the wild type. Herpes thymidine kinase purified from other mutants that formed colonies at higher thymidine concentrations than that of the wild type exhibited a decrease in kcat. The kcat of one of these mutant thymidine kinases was 10(-4) of that of the wild type enzyme. This study demonstrates that a spectrum of mutant enzymes with different catalytic properties can be obtained by selection from a plasmid with random sequence substitutions and this can be done in the absence of rational protein design.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8140098     DOI: 10.1093/protein/7.1.83

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  6 in total

1.  Systematic exploration of active site mutations on human deoxycytidine kinase substrate specificity.

Authors:  Pinar Iyidogan; Stefan Lutz
Journal:  Biochemistry       Date:  2008-03-25       Impact factor: 3.162

Review 2.  On the failure of de novo-designed peptides as biocatalysts.

Authors:  M J Corey; E Corey
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

Review 3.  In vivo versus in vitro screening or selection for catalytic activity in enzymes and abzymes.

Authors:  J Fastrez
Journal:  Mol Biotechnol       Date:  1997-02       Impact factor: 2.695

4.  Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.

Authors:  M E Black; T G Newcomb; H M Wilson; L A Loeb
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

5.  Engineering Kinases to Phosphorylate Nucleoside Analogs for Antiviral and Cancer Therapy.

Authors:  Stefan Lutz; Lingfeng Liu; Yichen Liu
Journal:  Chimia (Aarau)       Date:  2009-11-01       Impact factor: 1.509

Review 6.  Bystander or no bystander for gene directed enzyme prodrug therapy.

Authors:  Gabi U Dachs; Michelle A Hunt; Sophie Syddall; Dean C Singleton; Adam V Patterson
Journal:  Molecules       Date:  2009-11-10       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.